Personal information

No personal information available

Activities

Employment (3)

Fractal Therapeutics: Cambridge , Massachusetts , US

2016-10-01 to present | CEO
Employment
Source: Self-asserted source
Arijit Chakravarty

Takeda Oncology: Cambridge, MA, US

2011-03-01 to 2016-09-30 | Director, Modeling & Simulation (DMPK)
Employment
Source: Self-asserted source
Arijit Chakravarty

Millennium Pharmaceuticals : Cambridge , Massachusetts , US

2004-08-06 to 2011-03-04 | Scientist 1 —> Senior Scientist 2 (In vivo pharmacology, translational medicine, computational biology )
Employment
Source: Self-asserted source
Arijit Chakravarty

Education and qualifications (2)

Dartmouth College Geisel School of Medicine: Hanover, NH, US

1996-09 to 2004-06 | Ph.D. (Biochemistry )
Education
Source: Self-asserted source
Arijit Chakravarty

Birla Institute of Technology and Science: Pilani, Rajasthan, IN

1991-07 to 1996-05 | M.Sc. Biological Sciences, B.Pharm. (Biological Sciences, Pharmacy)
Education
Source: Self-asserted source
Arijit Chakravarty

Professional activities (2)

Dartmouth College: Hanover, NH, US

2019-09-01 to present | Advisory board member (Guarini Graduate School)
Invited position
Source: Self-asserted source
Arijit Chakravarty

Carnegie Mellon University: Pittsburgh, PA, US

2008-06-01 to 2017-03-01 | Adjunct assistant professor (Computational Biology )
Invited position
Source: Self-asserted source
Arijit Chakravarty

Works (11)

Machine learning for the identification of respiratory viral attachment machinery from sequences data

PLOS ONE
2023-03-02 | Journal article
Contributors: Kenji C. Walker; Viswanathan V. Krishnan; Maïa Shwarts; Stepan Demidikin; Arijit Chakravarty; Diane Joseph-McCarthy
Source: check_circle
Crossref

Antibody escape, the risk of serotype formation, and rapid immune waning: modeling the implications of SARS-CoV-2 immune evasion

2023-01-26 | Preprint
Contributors: Catherine Albright; Debra Van Egeren; Aditya Thakur; Arijit Chakravarty; Laura F. White; Madison Stoddard
Source: check_circle
Crossref

Vaccines alone cannot slow the evolution of SARS-CoV-2

2022-10-06 | Preprint
Contributors: Debra Van Egeren; Madison Stoddard; Laura F. White; Natasha S. Hochberg; Michael S. Rogers; Bruce Zetter; Diane Joseph-McCarthy; Arijit Chakravarty
Source: check_circle
Crossref

Machine Learning for the Identification of Viral Attachment Machinery from Respiratory Virus Sequences

2022-01-27 | Preprint
Contributors: Stepan Demidkin; Maïa Shwarts; Arijit Chakravarty; Diane Joseph-McCarthy
Source: check_circle
Crossref

Rapid relaxation of pandemic restrictions after vaccine rollout favors growth of SARS-CoV-2 variants: A model-based analysis

PLOS ONE
2021-11-24 | Journal article
Contributors: Debra Van Egeren; Martial L Ndeffo Mbah; Madison Stoddard; Alexander Novokhodko; Michael S. Rogers; Diane Joseph-McCarthy; Bruce Zetter; Arijit Chakravarty
Source: check_circle
Crossref

Using mixed-effects modeling to estimate decay kinetics of response to SARS-CoV-2 infection

Antibody Therapeutics
2021-07-19 | Journal article
Contributors: Dean Bottino; Greg Hather; L Yuan; Madison Stoddard; Lin White; Arijit Chakravarty
Source: check_circle
Crossref

The specter of Manaus: the risks of a rapid return to pre-pandemic conditions after COVID-19 vaccine rollout

2021-05-18 | Other
Contributors: Debra Van Egeren; Madison Stoddard; Alexander Novokhodko; Michael Rogers; Diane Joseph-McCarthy; Bruce Zetter; Arijit Chakravarty
Source: check_circle
Crossref

Controlling long-term SARS-CoV-2 infections is important for slowing viral evolution

2021-04-17 | Other
Contributors: Debra Van Egeren; Alexander Novokhodko; Madison Stoddard; Uyen Tran; Diane Joseph-McCarthy; Arijit Chakravarty
Source: check_circle
Crossref

In the long shadow of our best intentions: Model-based assessment of the consequences of school reopening during the COVID-19 pandemic

PLOS ONE
2021-03-25 | Journal article
Contributors: Kaitlyn E. Johnson; Giovanni Lo Iacono; Madison Stoddard; Ryan P. Nolan; Douglas E. White; Natasha S. Hochberg; Arijit Chakravarty
Source: check_circle
Crossref

Dose Optimization for Anticancer Drug Combinations: Maximizing Therapeutic Index via Clinical Exposure-Toxicity/Preclinical Exposure-Efficacy Modeling.

Clinical cancer research : an official journal of the American Association for Cancer Research
2019-07-18 | Journal article
Source: Self-asserted source
Arijit Chakravarty

Growth rate analysis and efficient experimental design for tumor xenograft studies.

Cancer informatics
2014-12-09 | Journal article
Source: Self-asserted source
Arijit Chakravarty